Tradestie Institutional Equity Comparison Engine
PYPD vs CLYM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
PYPD Overall Edge
PYPD Captures Institutional Edge (2โ1 Pillars ยท 2โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to PolyPid Ltd. Ordinary Shares (PYPD) driven by superior Momentum & Technical, Options & Structure while CLYM counters with relative strength in Growth & Margin. Fundamentally, PYPD trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CLYM at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, PYPD sits in BREAKOUT (12th %ile IV; Dealer Gamma Walls on Pro) against CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
PYPD N/M vs CLYM N/M Fwd P/E
Growth & Margin Winner
CLYM
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
PYPD
1Y +79.2% vs +406.8% ยท 52W Pos 80% vs 48%
Options & Structure Winner
PYPD
BREAKOUT (12th %ile IV) vs UNCLASSIFIED (N/A IV)
PYPD
NASDAQ
PolyPid Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.43
+4.63% 1D
Market Cap
$132.2M
1M Return
+31.86%
1Y Return
+79.25%
Forward P/E
N/M
Unified AI Score
31.1 / 100
SELL
Tech 50.0
Fund 27.0
Flow 56.0
Mom 32.0
CLYM
NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.63
-3.12% 1D
Market Cap
$608.5M
1M Return
-1.03%
1Y Return
+406.84%
Forward P/E
N/M
Unified AI Score
45.7 / 100
HOLD
Tech 41.0
Fund 47.0
Flow 50.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
PYPD +79.25%
CLYM +406.84%
Spread: +327.59 pp (CLYM Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
PYPD TTM Op. Margin: 0.0%
CLYM TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PYPD vs CLYM. Trailing 12-month operating profitability (PYPD 0.0% vs CLYM 0.0%) and valuation multiples (PYPD N/M vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | PYPD | CLYM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $132.2M | $608.5M | Larger Scale | CLYM |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -243.6% | -29.3% | Higher ROE | CLYM |
| 52-Week Range Position Momentum | 80% ($4โ$7) | 48% ($2โ$18) | Stronger Trend | PYPD |
| Beta / 30D Volatility Risk Regime | 0.89ฮฒ ยท 59% Vol | 1.52ฮฒ ยท 112% Vol | Lower Realized Risk | PYPD |
| Unified Institutional Score Composite Signal | 31.1 / 100 (SELL) | 45.7 / 100 (HOLD) | Higher Composite | CLYM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full PYPD vs CLYM Buy Guide
PYPD
BREAKOUT
40d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
12th %ile
IV Regime
Compressed (<25th %ile)
CLYM
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither PYPD nor CLYM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.